# Drawing parallels between amyloid PET in Alzheimer’s disease and amino acid PET in primary and secondary brain tumors

## TL;DR

This paper compares the development of amyloid PET in Alzheimer's disease to amino acid PET in brain tumors, suggesting a similar future for the latter.

## Contribution

The paper draws a novel analogy between amyloid PET in Alzheimer’s and amino acid PET in brain tumors, suggesting a similar trajectory for clinical adoption.

## Key findings

- Amino acid PET improves diagnostic accuracy and treatment planning in brain tumors.
- It helps distinguish tumor progression from treatment effects.
- Amino acid PET may become a key tool in precision medicine and clinical trials.

## Abstract

The evolution of amyloid PET in Alzheimer’s disease illustrates the potential path of amino acid PET in neuro-oncology. Initially seen as of limited value, amyloid PET ultimately enhanced diagnostic accuracy, guided management, and became central once therapies demonstrated PET-measured efficacy. Amino acid PET for CNS tumors is at a similar turning point. It refines diagnosis, distinguishes progression from treatment effects, and supports treatment planning. As demand grows and tracer access improves, amino acid PET could follow amyloid PET’s trajectory: emerging as a key tool in precision medicine and clinical management and as a surrogate endpoint in therapeutic trials.